255 related articles for article (PubMed ID: 22131341)
1. Interferon-α-based immunotherapy in metastatic renal cell carcinoma patients with the primary tumor in situ.
Shinohara N; Abe T; Sazawa A; Maruyama S; Shindo J; Sato S; Suzuki S; Nonomura K
Jpn J Clin Oncol; 2012 Feb; 42(2):113-9. PubMed ID: 22131341
[TBL] [Abstract][Full Text] [Related]
2. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study.
Bex A; Kerst M; Mallo H; Meinhardt W; Horenblas S; de Gast GC
Eur Urol; 2006 Jan; 49(1):76-81. PubMed ID: 16310929
[TBL] [Abstract][Full Text] [Related]
3. Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma.
Shinohara N; Kumagai A; Kanagawa K; Maruyama S; Abe T; Sazawa A; Nonomura K
Jpn J Clin Oncol; 2009 Nov; 39(11):720-6. PubMed ID: 19684042
[TBL] [Abstract][Full Text] [Related]
4. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
5. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma.
Jeon SH; Chang SG; Kim JI
Anticancer Res; 1999; 19(6C):5593-7. PubMed ID: 10697624
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
Hong SK; Kwak C; Lee SE
Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
[TBL] [Abstract][Full Text] [Related]
7. Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis.
Bex A; Haanen JB; Vyth-Dreese FA; Horenblas S; de Gast GC
Urol Int; 2008; 80(4):367-71. PubMed ID: 18587246
[TBL] [Abstract][Full Text] [Related]
8. Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level.
Akaza H; Tsukamoto T; Fujioka T; Tomita Y; Kitamura T; Ozono S; Miki T; Naito S; Zembutsu H; Nakamura Y
Jpn J Clin Oncol; 2011 Aug; 41(8):1023-30. PubMed ID: 21642665
[TBL] [Abstract][Full Text] [Related]
9. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.
Thomas AA; Rini BI; Lane BR; Garcia J; Dreicer R; Klein EA; Novick AC; Campbell SC
J Urol; 2009 Feb; 181(2):518-23; discussion 523. PubMed ID: 19100579
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.
Flanigan RC; Mickisch G; Sylvester R; Tangen C; Van Poppel H; Crawford ED
J Urol; 2004 Mar; 171(3):1071-6. PubMed ID: 14767273
[TBL] [Abstract][Full Text] [Related]
12. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
Flanigan RC; Salmon SE; Blumenstein BA; Bearman SI; Roy V; McGrath PC; Caton JR; Munshi N; Crawford ED
N Engl J Med; 2001 Dec; 345(23):1655-9. PubMed ID: 11759643
[TBL] [Abstract][Full Text] [Related]
13. [Immunotherapy in the management of metastatic renal carcinoma].
Fischetti G; Cuzari S; Leone P; De Martino P; Musy M; Mariani S; Fraioli A; Valentini MA
Minerva Urol Nefrol; 2002 Jun; 54(2):113-7. PubMed ID: 12070458
[TBL] [Abstract][Full Text] [Related]
14. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
17. Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
Donini M; Buti S; Lazzarelli S; Bozzetti R; Rivoltini L; Camisaschi C; Castelli C; Bearz A; Simonelli C; Lo Re G; Mattioli R; Caminiti C; Passalacqua R;
Target Oncol; 2015 Jun; 10(2):277-86. PubMed ID: 25230695
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study.
Spencer WF; Linehan WM; Walther MM; Haas GP; Lotze MT; Topalian SL; Yang JC; Merino MJ; Lange JR; Pockaj BA
J Urol; 1992 Jan; 147(1):24-30. PubMed ID: 1729540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]